Novel Nargenicin A1 Analog Inhibits Angiogenesis by Downregulating the Endothelial VEGF/VEGFR2 Signaling and Tumoral HIF-1α/VEGF Pathway

Targeting angiogenesis is an attractive strategy for the treatment of angiogenesis-related diseases, including cancer. We previously identified 23-demethyl 8,13-deoxynargenicin (compound 9) as a novel nargenicin A1 analog with potential anticancer activity. In this study, we investigated the antiang...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Jang Mi, Choi, Ye Seul, Dhakal, Dipesh, Sohng, Jae Kyung, Jung, Hye Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460547/
https://www.ncbi.nlm.nih.gov/pubmed/32751120
http://dx.doi.org/10.3390/biomedicines8080252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460547/
https://www.ncbi.nlm.nih.gov/pubmed/32751120
http://dx.doi.org/10.3390/biomedicines8080252

Ejemplares similares